

References

- Abeloff Martin D., Roy A. Beveridge, Ross C. Donehower, John H. Fetting, et al: Sixteen-Week Dose-Intense Chemotherapy in the Adjuvant Treatment of Breast Cancer. Journal of the National Cancer Institute, 2004; Vol. 82, No. 7, 570-574.
- Arnold D and Lesnick G: Survival following mastectomy for stage III breast cancer. Am. J. Surg.; 1979; 137: 362.
- Baclesse F.: Five-year results in 431 breast cancers treated solely by roentgen rays. Ann Surg 1965; 161:103–104.
- Baker R, Montogu A, Childs J: A comparison of modified radical mastectomy to radical mastectomy in the treatment of operable breast cancer. Ann. Surg.; 1979; 189: 553.
- Bartelink H, Rubens RD, van der Schueren E, Sylvester R. Hormonal therapy prolongs survival in irradiated locally advanced breast cancer: a European Organization for Research and Treatment of Cancer randomized phase III trial. J Clin Oncol 1997; 15(1):207-15.
- Barth V: Atlas of diseases of breast. George Thieme, Stuttgart; 1979.
- Barth: Comparison of Modified radical mastectomy to radical mastectomy in the treatment of operable breast cancer. Ann Surg 1970; 189; 553.
- Bassett MJ, Kimme Smith C, Sutherland LK et al.,: Automated and hand- held breast U.S.: Effect on patient management. Radiology 1987; 165: 103 – 108.

-Baum M, Budzar AU, Cuzick J et al.: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. *Lancet* 2002; 359(9324):2131-9.

-Bays JK: Physical and Mammographic diagnosis of breast cancer and initial workup. *JAMA*. 1992; 47: 158 – 160.

-Bear HD, Anderson S, Brown A, and Smith R, Mamounas P, Fisher B, et al.: The effect on tumor response of adding preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project protocol B-27. *J Clin Oncol* 2003; 21(22):4165-74.

-Bennefoi H, Diebold-Berger S, Therasse P: Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumor that predict for 5 year clinical outcome. *Am. Oncol.*; 2003; 14: 406-413

-Bhatty I, Shaharyar, Ibrahim M & Chaudhry ML: Complication of modified radical mastectomy. *Pak. J. Med. Sci.*; 2004, 20(2): 125-130.

-Bland K I and Vezeridis M P: The breast, *Anatomy of the breast and modified radical mastectomy with early or delayed reconstruction from Mastery of Surgery*, Edited by Lloyd M, Robert J Baker and Josef E Fisher, 4th eds, 2001, chapter 42, 46.

- Bland K I, Copeland EM: The Breast: Comprehensive Management of Benign and Malignant Disease. Philadelphia: Saunders, 1991.

- Boccardo F.: Switching to anastrozole (ANA) vs. continued tamoxifen (TAM) treatment of early breast cancer (EBC). Updated results of the Italian tamoxifen anastrozole (ITA) trial. Paper presented at: 41st Annual Meeting of the American Society of Clinical Oncology (ASCO), 2005; Orlando, United States.

- Boerner S, Sneige N. Specimen adequacy and false negative diagnosis rate in fine-needle aspirates of palpable breast masses. Cancer (Cancer Cytopathology) 1998; 84:344–48.

- Botti C, Vici P, Lopez M: Prognostic value of lymph node metastases after neoadjuvant chemotherapy for large-sized operable carcinoma of the breast. J Am Coll Surg, 1995; 181: 202-208.

- Brito RA, Valero V, Buzdar AU, Booser DJ, Ames F, Strom E, et al. Longterm results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: the University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol 2001; 19(3):628-33.

- Broadwater JR, Edwards MJ, Kuglen C, et al: Mastectomy following preoperative chemotherapy strict operative criteria control operative morbidity. Ann Surgery; 1991, 213: 126 - 9.

- Broët P, Scholl SM, de la Rochefordière A, Fourquet A, Moreau T, De Rycke Y, et al.: Short and long-term effects on survival in breast cancer

patients treated by primary chemotherapy: an updated analysis of a randomized trial. *Breast Cancer Res Treat* 1999; 58:151-6.

-Bundered NJ, Morgan DL, and Dixon JM: Management of regional nodes in breast cancer in: Dixon JM, Sainsbury JR; et al (ed.): *disease of breast*. First published by BMJ group. London, 1995; P.: 30-33.

-Buzdar AU, Singletary SE, Theriault RL, Booser DJ, Valero V, Ibrahim N, et al.: Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. *J Clin Oncol* 1999; 17(11):3412-17.

-Buzdar AU: Breast cancer in men. *Oncology (Huntingt)* 17:1361, 1998.

-Carlson R, et al.: Treatment of breast cancer in countries with limited resources. *The Breast J.*; 2003; Vol. 9. Suppl. 2. P.;567-574.

-Carter CL, Allen C, Henson DE: Relation of tumor size, lymph node status, and survival in 24, 740 breast cancer cases. *Cancer*: 1989; 63: 181-187.

-Casper ES, Guidera CA, Bosl GJ, Hakes TB, Kaufman RJ, and Shurgot B, et al.: Combined modality treatment of locally advanced breast cancer: adjuvant combination chemotherapy with and without doxorubicin. *Breast Cancer Res Treat* 1987; 9:39-44.

-Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, et al: Prospective randomized trials of docetaxel versus doxorubicin in patients

with Metastatic breast cancer. The 303 Study Group. J. Clin. Oncol. 1999; 17: 2341-54.

-Chollet P, Charrier S, Brain E, Cure H, van Praagh I, Feillel V, de Latour M, Dauplat J, Misset JL, Ferriere JP.: Clinical and pathological response to primary chemotherapy in locally advanced breast cancer, Eur J Cancer 2002; 33:862-6.

-Coombes RC, Hall E, Gibson L J et al.: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004; 350(11):1081-92.

-Cotran R, Humar V and Robbin S: Robbin's pathologic bases of disease, 5th ed. Philadelphia: W.B. Saunders, 1994.

-Crowe JP Jr, Gordan NH, Shenk RR, Zolinger RM Jr, Brunberg DJ and shuck JM: Primary tumor size. Relevance to breast cancer survival. Arch. Surg. 1992; 127: 910.

-Dasgupta S, Sanyal S, Sengupta SP: Transpectoral anterior approach to the axilla for lymph node dissection in association with mastectomy preserving both pectoral muscles and their neurovascular bundles. Tumori. 1999; 85(6):498-502.

-De Lena M, Zucali R, Viganotti G et al.: Combined chemotherapy radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemother Pharmacol 1978; 1:53–59.

-De Placido S, Perrone F, Carlomagno C, Morabito A, Pagliarulo C, Lauria R, et al.: CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study). Br J Cancer 1995; 71(6):1283-7.

-De-Matteis A, Montella M, Iannuzzo M, De-Mearco MR, et al.: Multimodal treatment strategy for LABC. J. Chemotherapy; 1998. Dec.; 10(6): 476-83.

-Derman DP, Browde S, Kessel IL, De Moor NG, Lange M, Dansey R, and et al.: Adjuvant chemotherapy (CMF) for stage III breast cancer: a randomized trial. Int J Radiat Oncol Biol Phys 1989; 17:257-61.

-Dhingra K, et al.: A phase III randomized trial of dose-intensive, neoadjuvant 5FU, doxorubicin, and cyclophosphamide with G-CSF in locally advanced breast cancer: efficacy and safety data. Proc Am Soc Clin Oncol 1999, 18:74a.

-Dixon JM, Ravi Sekar O, Walsh J et al: Specimen orientated radiography helps define excision margins of malignant lesions detected by breast screening. Br. J. Surg. 1993; 80 : 1001 – 1002.

-Dixon JM, Sainsbury JR, and Masterton G: Disease of the breast, 2nd ed. London; 1998, p. 103-142.

-Donehower LA, and Bradly A: The tumor suppressor p. 53, Bioch. Biophys.,Acta.:1993; 1155: 181-220.

-Eby N, Chang Claude J, Bishop DT: Familial risk and genetic susceptibility for breast cancer. Cancer causes Control. 1994; 5 : 458.

- Edeiken S: Mammography and Palpable cancer of the breast Cancer; 1988; 61 : 263- 265.

- Edward RS, Burton LE, John PH, Faith DO, Marcia CB, Lori JG and Lawrence JS: Postmastectomy morbidity after combination preoperative irradiation and chemotherapy for locally advanced breast cancer. World J. Surgery. Springer New York. 2003; 17; 237-241

- El Bolkainy M: Breast cancer. In: topographic pathology of cancer. 2nd ed. The National Cancer Institute. P.; 87; 2000.

- El Khattib O: WHO. East Mediterranean Office, 2003.

- EL Noweim S, Kohail H, and Omran A: Combined modality approach of locally advanced breast cancer with conservative surgery. J. Egypt Nat. Cancer Inst.; 1995; 7(1); 123-130 .

- Elledge RM, Fuqua SA, Clark GM, Pujol P, and Allred DC: The role and prognostic significance of p53 alteration in breast cancer. Breast Cancer Res. Treat.: 1993; 27: 95-110.
- Elliott RA. Jr., Hoehn JG and Germinger RF: correction of asymmetrical breasts. Plast. Reconstr. Surg., 1975; 56: 260.

- Eremin O, et al.: Chemotherapy in breast cancer: enhanced response with docetaxel. Proc Am Soc Clin Oncol 1999, 18:72a.

- Espinosa, E, Morales S, Borrega P, Casas A, Madroñal C, et al: Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in

locally advanced breast cancer. In: Cancer Chemotherapy and Pharmacology, V.; 54, N.; 6, Springer; 2004, pp. 546-552(7).

-Eva Singletary S: Neoadjuvant chemotherapy in the treatment of stage II and III. American Journal of Surgery, 2001; 182: 341 - 346.

-Fallowfield L, Cella D, Cuzick J et al.: Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol 2004; 22(21):4261-71.

-Feller WF, Holt R, and Spear S, et al.: Modified radical mastectomy with immediate breast reconstruction. Am Surg 52 (3): 129-33, 1986.

-Fisher B, Anderson S, Bryant J, et al.: Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347 (16): 1233-41, 2002.

-Fisher B, Bryant J, Wolmark N et al.: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 2672–2685.

-Fisher B, Fisher ER, Redmond C, et al.: Tumor nuclear grade, estrogen receptor, and progesterone receptor: their value alone or in combination as indicators of outcome following adjuvant therapy for breast cancer. Breast Cancer Res Treat 7 (3): 147-60, 1986.

-Fisher B, Rockette H, and Robidoux A, et al.: Effect of postoperative therapy for breast cancer on locoregional disease: first report of NSABP B-18. Proc. Ann. Meet Am. Soc. Clin. Oncol; 1994; 13: 64.

- Fisher ER, Fisher B, and Sass R: Pathologic finding from the NSABP: Bilateral breast cancer. *Cancer*; 1984; 54: 2002.
- Fletcher GH, Montague ED.: Radical irradiation of advanced breast cancer. *Am J Roentgenol* 1965; 93:573–584?
- Folk SJ: Radiotherapy and management of the axilla in early breast cancer. *Br. J. Surg.*, 2000; 81:1277-1281.
- Goble S and Bear HD: Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions. *Surg Clin North Am* 83: 943-971, 2003.
- Gogas J, Markopoulos C, Skandalakis P and Gogas H: Bilateral breast cancer. *Am. Surg.*; 1993; 59: 733.
- Greenall MJ: Benign conditions of the breast, *Oxford Text book of G. Surgery*; 1994.
- Grham, Mary V, Carlos A, and Peraze, et al.: Locally advanced carcinoma of the breast: Results and comparison of various treatment modalities. *Int. J. Radiol. Oncol. Biol. Phys.*; 1991; Vol.; 21; pp;311-318.
- Grham, Mary V, Carlos A, and Peraze, et al.: Locally advanced carcinoma of the breast: Results and comparison of various treatment modalities. *Int. J. Radiol. Oncol. Biol. Phys.*; 1991; Vol.; 21; pp;311-318.
- Gump FE: Lobular Carvinoma In situ (LCIS): Pathology and treatment. *J. Cell Biochem. Suppl.*, 1993; 17-53.

-Gupta R, Sinnett D, Carpenter R, Preece PE, and Royle GT: Antibiotic prophylaxis for post-operative wound infection in clean elective breast surgery. *Eur J Surg Oncol* 2000;26:363-366.

-Haagensen CD and Stout AP: Carcinoma of the breast. II. Criteria of operability. *Ann. Surg.*; 1943; 118: 859-868.

-Haagensen CD, and Bodian CA, et al.: A personal experience with Halsted's radical mastectomy. *Ann. Surg.*; 1998; 7: 143-150.

-Haagensen CD: Cancer Breast. In: Disease of the breast. 3rd edition. Haagensen CD (ed.): W. B. Saunders, Philadelphia, 808, 1986.

-Hagay C, Cherel P, de Maulmont C, et al: Contrast-enhanced CT mammography: evaluation in local breast cancer recurrence. *Radiology*; 1993; 1894; 4: 497.

-Halsted WS: The results of operations for the cure of cancer of the breast performed at John Hopkin's hospital from June 1889 to January 1894.

-Harms SE, Flaming DP, and Evans WP et al.: MR Imaging of the breast: Current status and future potential. *Ann. J. Radiat.* 1994; 163 : 1039 – 1047.

-Harold Ellis, Gene L, and John E: Skandakis, Surgical anatomy and Embryology of the breast and its related anatomic structures. *Surg. Clin.* August, 1993.

-Harris J, Morrow M, and Norton L: Malignant tumors of the breast. In; Cancer Principles and Practice of Oncology. 5th ed. Lippincott-Raven: 1997: 1542.

-Harris J: Staging of Breast cancer. In: Disease of the Breast. 2nd ed. Edited by Harris J. Lippincott. Williams and Wilkins. Philadelphia, 2000.

-Harris JR, Recht A, and Conolly J: Conservative surgery and radiotherapy for Early Breast Cancer. Cancer, 1993; 66: 1427.

-Helvie MA, Joynt LK, Cody RL, Pierce LJ, Adler DD, and Merajver SD: Locally advanced breast carcinoma: accuracy of mammography versus clinical examination in the prediction of residual disease after chemotherapy. Radiology 1996; 198:327-32.

-Henderson C, Harris JR, Kinne DW, Hellman S.: Cancer of breast. In: Devita Jr VT, Hellman S, Rosenberg SA, editors Cancer: Principles and Practice of Oncology. 3rd edition Philadelphia, JB Lippincott Co 1998; 1217.

-Henderson IC, Harris JR, Kinne DW and Hellman S: Cancer of the breast. In De vita VT, Helman S, Rosenberg SA (eds): cancer: Principles and practice of Oncology, pp 1197 – 1268. Philadelphia: JB. Lippincott, 1989.

-Hirshaut, Y., & Pressman, P. I. et al: Breast cancer: The complete guide. New York. 1996: 26, 651–664.

-Hoefer RA Jr, JJ DuBois, LB Ostrow, and LF Silver: Wound complications following modified radical mastectomy: an analysis of perioperative factors J Clin Oncol 2002; 20:1456-66.

-Højris I, Overgaard M, and Christensen JJ, et al.: Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials. Radiotherapy Committee of the Danish Breast Cancer Cooperative Group. Lancet 354 (9188): 1425-30, 1999.

-Homer MJ: Breast Imaging: pitfalls, controversies and some practical thoughts. Radiological Clinics of North America; 1985, 23(3): 459-472.

-Honkoop AH, et al.: Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer. Am J Clin Pathol 1997, 107:211-218.

-Hortobagyi GN, Ames FC, Buzdar AU, et al: Management of stage III primary breast cancer with primary chemotherapy, surgery and radiation therapy. Cancer; 1988; 62: 2507 - 16.

-Hortobagyi GN, Buzdar AU: Locally advanced breast cancer: A review including the M.D. Anderson experience. In: Ragaz J. Ariel IM(eds.): High risk Breast Cancer. Berlin, Springer-Verlag, 1991.

-Hortobagyi GN, Singletary SE, Strom EA.: Treatment of locally advanced and inflammatory breast cancer. In: Harris JR, Lippman ME,

Morrow M, Oxborne CK, editors. Diseases of the breast. 2nd ed. Philadelphia: Lippincott Williams and Wilkins; 2000. P.645-60.

-Howell A et al.: Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: A multinational, double-blind, randomized trial. J Clin Oncol 2004; 22(9):1605-13.

-Hryniuk W and Levine M: Analysis of dose intensity in chemotherapy trials in stage II breast cancer J. Clin. Oncol.; 1986; 4 : 1162.

-Hutter RVP: The influence of pathologic factor on breast cancer management. Cancer; 1980, 46: 961-976.

-Iglehart JD: Breast. In: Textbook of surgery, 14th ed. Sabiston DC (ed.): W.B. Saunders. Co. Philadelphia. Vol. 1, P. 510, 1991.

-Ingram DM, Nottage E and Robert S: the role of diet in the development of breast cancer: A case. Control study of patients with breast cancer, benign epithelial hyperplasia and fibrocystic disease of the breast. Br. J. cancer: 1991; 64: 187.

-Ionta MT, Scanu A, Atzori F et al: Prolonged neoadjuvant chemotherapy in locally advanced breast cancer patients: A prognostic role to disease free survival (DFS) and overall survival (OS). Ann Oncol 2002; 13 Suppl.5:43.

-Jackson VP: The role of U.S. in breast imaging. Radiology. 1990; 177 : 305 – 311.

-Jager W, Eibner K, Loffler B, Gleixner S, Kramer S: Serial CEA and CA 15.3 during follow-up of breast cancer patients. *Anticancer Res* 2000; 20: 5179–5182.

-Jain V, Landry M, and Levine: The stability of estrogen and progesterone receptors in patients receiving preoperative chemotherapy for locally advanced breast carcinoma. *Am. Surgery*; 1996; 62: 162-5.

-Jardines L, Fowble B, and Schultz D, et al.: Factors associated with a positive reexcision after excisional biopsy for invasive breast cancer. *Surgery* 118 (5): 803-9, 1995.

-Jardines L, Haffy BG, and Doroshow J: Breast cancer overview. In: *Textbook of Cancer Management: A multidisciplinary approach*. 6th ed. RRR-Melville. NY.: 2002: p. 149-212.-Johnston SR et al.: Life following aromatase inhibitors — Where now for endocrine sequencing? *Breast Cancer Res Treat* 2005; 93(Suppl 1):19-25.

-Jardines L, Haffy BG, and Doroshow J: Breast cancer overview. In: *Textbook of Cancer Management: A multidisciplinary approach*. 6th ed. RRR-Melville. NY.: 2002: p. 149-212.

-Karlsson YA, Malmstrom PO, Hatschek T, Fornander TG, Soderberg M, Bengtsson NO et al.: Multimodality treatment of 128 patients with locally advanced breast carcinoma in the era of mammography screening using standard polychemotherapy with 5-fluorouracil, epirubicin, and cyclophosphamide: prognostic and therapeutic implications. *Cancer* 1998; 83: 936-47.

- Karnon J, Johnston SRD, Delea TE et al.: Cost-effectiveness of extended adjuvant letrozole after five years of tamoxifen in postmenopausal early breast cancer. *J Clin Oncol* 2004; 22(14S):6044.

- Kasseroller G: The Vodder School; the Voder method. *Cancer* 1998; 83: 2840.

- Khanusur T, Haick A, and Patel B: Evaluation of bone scan as a screening work up in 1ry and locoregional recurrence of breast cancer. *Am. J. Clin. Oncol.*; 1987: 10: 167.

- Kinne DW and Kopans DB: Physical examination and mammography in the diagnosis of breast disease. In Harris JR, Hellman S, Henderson IC, (eds): *Breast Diseases*, Philadelphia, JB Lippincott, 1993.

- Klefstrom P, Grohn P, Heinonen E, Holsti L, Holsti P. Adjuvant postoperative radiotherapy, chemotherapy, and immunotherapy in stage III breast cancer. II. 5-year results and influence of levamisole. *Cancer* 1987; 60(5):936-42.

- Kopans DB, Mayer JE, and Cohen AM: Palpable breast masses: the importance of preoperative mammography. *JAMA*, 1981, 246(24), 2819-2882.

- Kuerer HM, Newman LA, Buzdar AU, et al: Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. *Am J Surg*, 1998; 176: 502-509.

-Kuerer HM, Newman LA, Smith TL, et al: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin based neoadjuvant chemotherapy. Clin. Oncol.; 1999, 17: 460.

-Kumar S, Sadhasivam, Saxena A, and Kathirval.S, Kannan TR et.al: The safety and efficacy of prophylactic ondansetron in patients under going modified radical mastectomy. Anaesth Analg.1999; 89:1340.

-Leduc O, Leduc A, Bourgeois P, Belgrado JP.: The physical treatment of upper limb edema. Cancer 1998; 83: 2835.

-Leis HP: Prognostic parameters for breast comprehensive management of benign and malignant diseases. W.B. Saunders Com.; Ed.; 1991: P.; 331-346.

-Lejour M: vertical mammoplasty for breast hypertrophy and ptosis, Op. Tech. Plast. Reconstr. Surg., 1996; 3(3): 189 – 198.

-Levitt M, Warr D, Yelle L, Rayner HL, Lofters WS, Perrault DJ, et al: Ondansteron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil. N. Engl. J. Med.; 1993; 328: 1081-4.

-Lieberman L, Cohen MA, Dershaw DD, et al. Atypical ductal hyperplasia diagnosed at stereotactic core biopsy of breast lesions: an indication for surgical biopsy. AJR Am J Roentgenol 1995;164(5):1111-3.

- Love S: Benign and malignant breast diseases in Rilchie WP, Steele G, Dean KH, (ed.). General surgery. Philadelphia, Lippincott, 1994.

- Maddox W, Carpenter J, et al. Radical versus MRM for breast cancer. Ann Surg 1983; 63:239.

- Makris A, Powles TJ, and Allred DC, et al.: Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot study. Breast Cancer; Research Treatment; 1999; 53: 519.

- Makris A, Powles TJ, Ashley SE, Chang J, Hickish T, Tidy VA, et al.: A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 1998; 9(11):1179-84.

- Martin JE, Moskowitz M, Milbrath JR: Breast cancer missed by mammography. American J. Roentgenology, 1979, 132: 737-739.

- Mauriac L, MacGrogan G, Avril A, Durand M, Floquet A, and Debled M, et al: Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 1999;10(1):47-52.
- Mc Divitt RW, Stevens JA, lee NC, Wingo PA, Rubin GL and Grsell D: Histological types of benign breast disease and the risk for breast cancer. Cancer. 1992; 69: 1408.

- Mc Divitt RW: Breast. In: Kissane JM (ed.) Anderson's Pathology, 1990 : 1726 – 1750.

- Mc Vay CB: Breast or mammary region In: Anson and Mc Vay Surgical Anatomy. 6th ed. P. 352, 1984.

- Me Ready DR, Hortobagyi GN, Kau SW, et al.: The prognostic significance of lymph node status after preoperative chemotherapy for locally advanced breast cancer. Arch. Surgery, 1989; 124:21-5.

- Meek AG: Breast radiotherapy and lymphedema. Cancer 83 (12 Suppl American): 2788-97, 1998

- Meric F, Mirza NQ, and Buzdar AU, et al.: Prognostic implications of pathological Lymph node status after preoperative chemotherapy for operable T2 N0 M0 breast cancer. Ann. Surgery Oncol, 2000; 7:435 - 40.

- Miller AB, Zacer JB, Berggren RB et al.: Breast reduction for symptomatic macromastia: Can objective predictors for operative success be identified? Plast. Reconstr. Surg. 1995 (1); 77-83.

- Miller KD, et al.: Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: a randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol 1999, 17:3033-3037.

- Molina R, Filella X, Alicarte J, Zanon G, Pahisa J, Muoz M, Farrus B, Ballesta AM: Prospective evaluation of CEA and CA 15.3 in patients with locoregional breast cancer. Anticancer Res 2003; 23: 1035–1041.

- Morrow M: The woman at increased risk for breast cancer; evaluation and management strategies cancer. Eur. J. cancer; 1995; Prev. 4; 7.

- Morrow, M., Gradishar, W. et al: Recent developments: Breast cancer. *BMJ*; 2005; 324: 410-414.
- Moschos SJ, Edington HD, Land SR, Rao UN, Jukic D, Shipe-Spotloe J, and Kirkwood JM: Neoadjuvant Treatment of Regional Stage IIIB Melanoma With High-Dose Interferon Alfa-2b Induces Objective Tumor Regression in Association With Modulation of Tumor Infiltrating Host Cellular Immune Responses *J. Clin. Oncol.*, July 1, 2006; 24(19): 3164 - 3171.
- Nabholtz JM, Falkson C, Campos D et al.: Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. *J Clin Oncol* 2003;21:968–975.
- National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. SEER Program Public Use Data Tapes 1973–1998, November 2000 Submission. Issued: April 2001.
- Nguyen M, McCombs MM, Ghandehari S, et al. An update on core needle biopsy for radiologically detected breast lesions. *Cancer* 1996;78(11):2340-5.
- Oberman HA: Metaplastic Carcinoma of the breast: A clinic pathologic study of 29 patients. *Am. J. Surg. Pathol.*, 1987; 11 : 918 – 929.
- Olson JE, Neuberg D, Pandya K, Richter MP, and Solin LJ, and Gilchrist KW, et al.: The role of radiotherapy in the management of operable locally advanced breast carcinoma. Results of a randomized trial

by the Eastern Cooperative Oncology Group. *Cancer* 1997; 79(6):1138-49.

-Omar S, and Contesso G: *Breast Cancer*. 4th ed. Cairo University Publications; 2001.

-Omar S, and Khaled H: Staging of breast cancer and end results of therapy. In: Omar S, and Contesso G. *Breast Cancer*. Published by Association Medical Franco-Egyptian. 3rd ed. P.; 17; 1997.

-Omar S, Hussein K, Gaafer R, Zekry A, Eissa S, and El Khateeb O: Under publication in the *Eastern Mediterranean Health J.*, 2002.

-Omar S, Khaled H, and Eissa S: *Pan Arab Oncology news Letter*. October, 2003.

-Orel SG, Schnall MD, Powell CM et al.: Staging of suspected breast cancer: Effect of MR imaging and MR guided biopsy. *Radiology* 1995; 196 : 115 – 152.

-Osborne CK, Kitten L, and Arteaga CL: Antagonism of chemotherapy induced cytotoxicity for human breast cancer by antiestrogens. *J. Clin. Oncol.*, 2002; 7: 710.

-Papaioannou A, Lissaios B, Vasilaros S, Miligos S, Papadimitriou G, Kondilis D, et al.: Pre- and postoperative chemoendocrine treatment with or without postoperative radiotherapy for locally advanced breast cancer. *Cancer* 1983; 51(7):1284-90.

-Paridaens R, Biganzoli L, Bruning P, Klijn JG, Gamucci T, et al: Paclitaxel versus doxorubicin as first line single-agent chemotherapy for Metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. *J. Clin. Oncol.*; 2000; 18: 724-33.

-Paulus DD: Lymphoma of the breast. *Radiol. Clin. North Am.* 1990; 28-833.

-Pazner RD, Patterson MP, Hill LR et al.: Arm lymphedema in patients treated conservatively for breast cancer; relationship to patient, age and axillary node dissection technique. *Int J Radiat Oncol Biol Phys* 1986; 12: 2079.

-Perter JC: Hormonal regulation of breast development and activity. *J. Invest. Dermatol*, 1974; 63: 85.

-Pierce S, Recht A and Lingos T: Long Term radiation complications following conservation surgery and radiation Therapy in patient with early stage breast cancer; *S. Biol. Phys.* 1996; Vol.; 23:915-923.

-Pogson CJ, Adwani A, Ebbs SR: Seroma following breast cancer surgery. *Eur J Surg Oncol* 2003, 29:711-717.

-Pollard SG, Marks PV, Temple LN and Thombson HH: Breast Sarcoma. A Clinicopathologic. Review of 25 cases. *Cancer.* 1990; 66: 1941.

-Pouillart P, et al.: Final results of a phase II randomized, parallel study of doxorubicin/cyclophosphamide and doxorubicin/Taxol as neoadjuvant

treatment of local-regional breast cancer. Proc Am Soc Clin Oncol 1999, 18:73a.

-Pruthi S. Detection and evaluation of a palpable breast mass. Mayo Clinic Proceedings 2001; 76:641-48.

-Ricbourg B: Applied anatomy of the breast: blood supply and innervations, Ann. Chir. Plast. Esthetic, 1992; 37 (6): 603 – 602.

-Robbins Sl, Cotran RS and Kumar V: Pathologic Basis of Disease.; 1995; 20 – 421.

-Romrell L J and Bland K1: Anatomy of the breast, axilla, chest wall, and related metastatic sites. In Bland K1, Copeland EM, (editors): The breast: Comprehensive management of benign and malignant diseases, Philadelphia, 1991, Saunders.

-Rosen PP, Saigo P, and Braum D: Axillary micrometastases and macrometastases in breast cancer. Ann. Surg.; 1981; 194: 586.

-Rubin E and Farber JL: Pathology, 2nd ed. Philadelphia. JB. Lippincott, 1994.

-Rush BF: Breast. In: Principles of Surgery, 7th edition. Schwartz SI. Tom GS and Spencer FC (eds): Library of Congress, New York, 1989; P. 549.

-Rustogi A, Budrukkar A, and Dinshaw K, Jalali R: Management of locally advanced breast cancer: Evolution and current practice

Department of Radiation Oncology, Tata Memorial Hospital, Parel, and Mumbai, India. 2005; I; 21: 30.

-Saskia R.J. and Thiadens, R.N.: Breast Cancer Surgery and Lymphedema: A Neglected Complication. . Br J Cancer 2005; 1: 7-13.

-Schneider J, Lucas R, and Sanchez J, et al.: Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDRI and LRP. Anticancer Research; 2000; 20: 4373-7.

-Schrenk P, Konstantiniuk S, Wöfl S, et al.: Prediction of non-sentinel lymph node status in breast cancer with a micrometastatic sentinel node. Br. J. Surg. 2005; 92 (6): 707-13.

-Seidman H, Gelb SK, Silverberg E et al. Survival experience in the Breast Cancer Detection Demonstration Project. CA Cancer J Clin 1987; 37:258–290.

-Seshadri R, Figgair FA, Horsfall DJ, McCaul K, Setlur V, and Kitchen P: Clinical significance of HER-2/ neu Oncogenes amplification in primary breast cancer. J. Clin. Oncol. 1993; 11: 1936-1970.

-Sharon H and Giordano: Update on locally advanced breast cancer. University of Texas M.D. Anderson Cancer Center. The Oncologist. 2003; 8: 521-530.

-Sikov WM: Neoadjuvant high-dose weekly paclitaxel in stage IIB-IIIB breast cancer: a BrUOG study. Breast Cancer Res Treat 1999, 57:68.

- Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, et al. Revision of the American Joint Committee on Cancer Staging System for Breast Cancer. *J Clin Oncol* 2002; 20(17); 3628-36.

- Sinie R, lesser M, Kinne D and Rosen P: Methods of Tumor detection influences disease free survival of women with breast cancer. *Cancer*; 1998; Vol. 23, p. 1666 – 1672.

- Skandalakis JE, Grayt SW and Rower JS: Anatomical complications of General surgery. Eward, Arnold (eds): London; 1995; P. 37.

- Smith IC and Dowsett FJ: Breast radiotherapy after lumpectomy, no longer always necessary. *N Engl J Med* 351 (10): 1021-3, 2003.

- Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, and Gilbert FJ, et al.: Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. *J Clin Oncol* 2002; 20(6):1456-66.

- Spanos WJ Jr, Montague ED, Fletcher GH.: Late complications of radiation only for advanced breast cancer. *Int J Radiat Oncol Biol Phys* 1980; 6:1473–1476.

- Spyratos F, Maudelode T, Brouillet JP, Brunet M, Defrenne A, Andrieu C, Hacene K, Desplaces A, Rouesse J, and Rochefort H: An independent prognostic factor for metastases of breast cancer. *Lancet*; 1989; 67: 8672: 1115.

- Stavors AT, Thikman D, Rapp Cl, et al.: solid breast nodule: Use of sonography to distinguish between benign and, malignant lesions. Radiology. 1995; 196 : 123 – 134.

- Steeg PS, De La Rosa A, Flatow U, MacDonald NJ, Benedict M, and Lecone A: Nm23 and breast cancer metastases. Breast Cancer Res. Treat.; 1993; 25: 175-188.

- Stewart JF, King RJ, Winter PJ, et al.: Oestrogen receptors, clinical features and prognosis in stage III breast cancer. Eur. J. Clin. Cancer Oncol.; 1982; 18: 1315-1320.

- Stieber P, Molina R, Chan DW, Fritsche HA, Beyrau R, Bonfrer JM, Filella X, et al: Clinical evaluation of the Elecsys CA 15.3 test in breast cancer patients. Clin Lab; 2003; 49: 15–24.

- Strom EA, McNeese MD, Fletcher GH, Romsdahl MA, Montague ED, Oswald MJ. Results of mastectomy and postoperative irradiation in the management of locoregionally advanced carcinoma of the breast. Int J Radiat Oncol Biol Phys 1991; 21(2):319-23.

- Susan HL, Maureen AC, Ruhul MQ, Margret MS, Blake C: The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression and hormone receptor status in breast cancer. Am. J. Surg.; 2003; 186 :348-350.

- Tabar L, Dean PB, and Pentock Z: Galactography: the diagnostic procedure of choice for nipple discharge. Radiology; 1983; 31: 149.

-Taber L, and Dean PB: Teaching atlas of mammography. Stuttgart-Thieme-Stratton. New York; 1985.

-Tannock IF, Boyed NF, DeBoer G, Erlichman C, Fine S, Larocque G, et al: A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with Metastatic breast cancer. J. Clin. Oncol. 1988; 6: 1377-87.

-Tara MB, Lisa C, Aysegul S, Jason BF, Henry MK, Lisa AN et al: Sentinel Lymph Node Biopsy Is Accurate After Neoadjuvant Chemotherapy for Breast Cancer. Journal of Clinical Oncology, Vol 18; 2000: 20; 3480-3486.

-Tavassoli FA: Pathology of the breast. New York: Elsevier Science, 1992.

-The American Joint Commission on Cancer (AJCC): AJCC manual for staging cancer. 5th edition. Philadelphia. Lippincott-Raven, publishers; 1997; 171-180.

-The Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998; 352: 930–942.

-Therasse P, Mauriac L, Welnicka-Jaskiewicz M, Bruning P, Cufer T, Bonnefoi H, et al. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment

in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. *J Clin Oncol* 2003; 21(5):843-50.

-Tsakraklides V, Olsen P, and Kersy J: Prognostic significance of the regional lymph node history in breast cancer. *Cancer*; 1974; 20: 1259.

-Valero V, et al.: Combined modality treatment of locally advanced breast cancer in elderly patients using tamoxifen as primary therapy. *Proc Am Soc Clin Oncol* 1998, 17:105a.

-Van Dam PA, Van Goetbem MLA, Kersschot E. et al.: Palpable solid breast masses: Retrospective single and multimodality evaluation of 201 lesions. *Radiology*. 1988; 166 : 435 – 439.

-Van der Hage JA, van de Velde CJH, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. *J Clin Oncol* 2001;19(22):4224-37.

-Vanik RK, Georgiade GS: Congenital and developmental breast anomalies In: Georgiad NG et al., eds. *Essentials of plastic, maxillofacial and reconstructive surgery*. Baltimore; Williams and Wilkins, 1987, 673.

-Vernon H, Henning M, Vladimir S, Erik J, Edouard V, Bridget AR, Vanina G, Michael M, Soeren C: Phase III Trial Comparing Three Doses of Docetaxel for Second Line Treatment of Advanced Breast Cancer. *JCO*. 2006: 4963-4970.

- Veronesi U, Cascinelli N and Greco M: Prognosis of breast cancer patients after mastectomy and dissection of internal mammary nodes. *Ann. Surg.*; 1999; 202: 702 – 707.
- Vetto JT, Pommier R, Schmidt W, et al. Use of the “triple test” for palpable breast lesions yields high diagnostic accuracy and cost savings. *Am J Surg* 1995; 169(5):519-22.
- Vetto JT, Pommier RT, Schmidt WA, et al. Diagnosis of palpable breast lesions in younger women by the modified triple test is accurate and cost effective. *Arch Surg* 1996; 131: 967-74.
- Viens P, et al.: First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial). *Br J Cancer* 2004, 81:449-456.
- Vinnicombe SJ, MacVicar AD, Guy RL, Sloane JP, Powles TJ, Knee G, Husband JE. Primary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathologic correlation, *Radiology* 1996; 198:333-40.
- Wargotz ES and Silverberg SG: Medullary carcinoma of the breast: A clinic pathologic study with appraisal of current diagnostic criteria. *Hum. Pathol.* 1988; 19-1340.
- Weber BL, Merjver SD, August DA, et al: High response rate and breast conservation in locally advanced breast cancer(LABC) using combined

modality therapy with hormonal synchronization. Proc. Am. Soc. Clin. Oncol.; 1992; 11:75.

-Weider N, Folkman J, Pozza F, Bevilacqua P, Allerd En, Moore Dh, Meli S, and Gasparini G: Tumor angiogenesis: a new significance prognostic indicator in early stage breast carcinoma. J. National Cancer Inst.; 1992; 84: 1875-1892.

-Welsch CW: Affiance and the development of the normal and neoplastic mammary gland. Proc. Soc. Exp. Bion. Med., 1994; 1-207.

-Wenger CR, Clark GM: S-phase fraction and breast cancer: a decade of experience. Breast Cancer Res.; 1997; 51: 255.

-Whitaker S and Battersby C: The dilemma of stage III breast cancer: A study of preoperative radiotherapy. Aust. N. Z. J. Surg.; 1977; 47: 684.

-Wilking N, Rutqvist L, Carstensen J, Mattsson A, and Skoog L: Prognostic significance of axillary nodal status breast cancer in relation to the number of resected nodes. Acta Oncology; 1992; 31: 29-35.

-William M and Sikov MD: Locally Advanced Breast Cancer . In: Current Treatment Options in Oncology. American Society of Clinical Oncology; 2000, 1:228-238.

-Winchester DP, and Lesnefsky MH: The breast, diagnostic approach to breast abnormality from Mastery of Surgery, Edited by Lloyd M. Nyhus, Robert J. Baker and Josef E. Fisher, 4th ed; 2001, chapter 43, p. 574-587.

-Winer PE, Morrow M, Osborne CK, and Harris JR: Cancer of the Breast, Chapter: 37. Malignant Tumors of the Breast: Cancer: Principles and Practice of Oncology, 6th Edition Published by Lippincott, Williams and Wilkins, Copyright 2001.

-Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001;30:96-102.

-Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma [published erratum appears in N Engl J Med ; 331(2):139]. N Engl J Med; 2005; 330(18):1253-9.

-Woodworth PA, McBoyle MF, Helmer SD, and Beamer RL: Seroma formation after breast cancer surgery: incidence and predicting factors. Am Surg 2000, 66:444-450.

-Wylie E: Malignant disease. In: Textbook of mammography. Edited by Tucker AK. Churchill-Livingstone; 1993; ch. 6; pp 82-116.

-Yeh T, Fowble B, Viglion MJ, Li Volsi V, and Schultz DJ: Pathologic assessment and pathologic prognostic factors in operable breast cancer. In: Fowble B, Goodman RL, Glick J, and Rosato E: Breast Cancer Treatment. Published by Mosby; 1991; P.: 167-202.